Shanghai confirms it's mulling a rival bid for Stada Arzneimittel

18 May 2017
mergers-acquisitions-big

Chinese drugmaker Shanghai Pharmaceutical (601607.SS) has confirmed media reports that it is in discussions with financial investors over a possible bid for German generics drugmaker Stada Arzneimittel (SAZ: Xetra).

The firm, which has a market value of $9 billion, added that that there were "a lot of uncertainties" in connection with the offer, saying that earlier reports of a bid of 70 euros ($78) per share were not true.

The Stada board recently indicated it was happy with an offer of 5.3 billion euros ($5.9 billion) to be bought by private-equity companies Bain Capital, from the USA, and London-based Cinven.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics